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Purpose
Reactive oxygen species (ROS) are generated as an indirect product of radiation therapy
(RT). Genetic variation in genes related to ROS metabolism may influence the level of 
RT-induced adverse effects. We evaluated the potential association of single nucleotide
polymorphism (SNP)–related response to radiotherapy injury in breast cancer patients 
undergoing RT.
Materials and Methods
Eighty patients receiving conventional RT were included. Acute effects were evaluated 
according to the Radiation Therapy Oncology Group (RTOG) scores. DNA was extracted from
blood and buccal swab samples. SNPs were genotyped for GSTP1, GSTA1, SOD2, and NOS3
genes by polymerase chain reaction–based restriction fragment length polymorphism. 
Univariate analysis (odds ratios [ORs] and 95% confidence interval [CI]) and principal com-
ponent analysis were used for correlation of SNPs and factors related to risk of developing
≥ grade 2 acute effects. 
Results
Sixty-five patients (81.2%) showed side effects, 32 (40%) presented moderate to severe
acute skin toxicity, and 33 (41.2%) manifested minimal acute skin reactions by the end of
treatment. In both univariate and multivariate analyses, nominally signiﬁcant associations
were found among body mass index (OR, 3.14; 95% CI, 8.5338 to 1.1274; p=0.022), breast
size (OR, 5.11; 95% CI, 17.04 to 1.54; p=0.004), and grade ≥ 2 acute radiation skin toxicity.
A significant association was also observed between NOS3 G894T polymorphism (OR, 9.8;
95% CI, 211.6 to 0.45; p=0.041) and grade ≥ 2 acute radiation skin toxicity in patients with
neo-adjuvant chemotherapy treatment.
Conclusion
The analysis of the factors involved in individual radiosensitivity contributed to the under-
standing of the mechanisms underlying this trait.
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Introduction
Survival rates for breast cancer (BC) have improved signif-
icantly in recent years due to new treatment options. How-
ever, BC remains a major killer in industrialized countries
[1]. In 2012, more than 408,000 women were diagnosed with
BC in Latin America and 92,000 died from the disease. Cur-
rent projections suggest a 46% increase during the next two
decades. Therefore, early detection and treatment advances
may improve management and survival of BC [2]. 
Radiation therapy (RT) is an important tool in the treat-
ment of BC [3]. It has been accepted as a well-established pro-
tocol after breast conserving surgery (BCS) for local tumour
control and to reduce the risk of loco-regional recurrence
[4,5]. However, this procedure presents adverse reactions in
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normal tissue, which are commonly classified as early and
late effects [6]. 
Acute effects occur during or shortly after treatment com-
pletion; they are usually reversible, manifest mainly in the
skin and can range from mild erythema and desquamation
to necrosis and ulceration. Late radiation toxicities can be
permanent; they occur from 6 months to several years after
treatment, and include subcutaneous fibrosis, athrophy, and
vascular damage [5,7]. The observed reactions can be dose-
limiting and may question a curative treatment intent. Con-
siderable technical efforts have been made to improve the
effective tumour dose and decrease the amount of normal
tissue inevitably included in the treatment volume [8]. As a
consequence, standard radiation doses may induce different
levels of early and late side effects, and the normal tissue 
response of patients will vary substantially [5,8].
Interindividual variability in normal tissue radiosensitivity
is a multifactorial trait. It depends on treatment parameters
such as total radiation dose and schedule, on clinical factors
such as age and lifestyle, and on a genetic component [9].
Normal tissue radiosensitivity is regarded as a complex poly-
genic trait resulting from the combined effects of multiple
common single nucleotide polymorphisms (SNPs) with
modest functional effects and low level of penetrance [10].
Several lines of evidence support a genetic basis for normal
tissue radiosensitivity; however, the speciﬁc genetic deter-
minants and the underlying molecular mechanisms are only
partly understood [9]. The main candidate genes involved in
the pathogenesis of radiotoxicity participate in mechanisms
of DNA damage repair, pro-inflammatory response, oxida-
tive stress, and damage sensing. 
RT exerts its cytotoxic effects through direct ionization of
DNA and the production of free radicals such as reactive
oxygen species (ROS) formed by radiolysis of water. These
ROS react with cellular macromolecules, especially DNA.
Thus, genetic variants in genes involved in protection from
oxidative stress could explain the increased acute toxicity,
i.e., higher incidence of erythema after a single dose [8].
Overexpression or diminished activity of antioxidant 
enzymes may strengthen the effectiveness of RT [1]. 
The enzymes that play a key role are manganese superox-
ide dismutase (SOD2), whose presence in the mitochondria
enables the dismutation of superoxide radicals to hydrogen
peroxide and oxygen, glutathione S-transferases (GSTs
alpha, mu, pi, and theta), which neutralize ROS, and pro-
oxidant enzyme endothelial nitric oxide synthase (NOS3), 
involved in the generation of reactive nitrogen species [11].
Few studies have evaluated the relationships of polymor-
phisms in oxidative stress–related candidate genes and acute
toxicity, while some independent studies have confirmed
correlation between them [1]. Nevertheless, some reports
support that SNPs in genes related to oxidative stress influ-
ence the occurrence of acute skin toxicity in patients with BC
[9,12]. However, more research is needed to conﬁrm the 
involvement of speciﬁc genetic variants.
In view of the above mentioned, we evaluated the associ-
ation of SNPs in genes related to enzymes involved in 
antioxidative activities (GSTP1, SOD2, NOS3, and GSTA1)
and the development of RT adverse acute effects in BC 
patients.
Materials and Methods
1. Subjects and data collection
The current prospective study was conducted with 
patients from La Plata city and surrounding areas attending
the Oncology Integrated Center, La Plata, Argentina. Eighty
samples were obtained from individuals with histologically
confirmed BC and after BCS (mean age, 59 years; age range,
26 to 79 years). The surgical procedure was quadrantectomy
in 83.75% of cases; 31.25% of patients had previously under-
gone chemotherapy with anthracyclines and taxanes or a
combination of both. Peripheral blood (5 mL in 5% ethylene-
diaminetetraacetic acid tubes) and buccal swabs were col-
lected. Clinical data (age, body mass index [BMI], breast size,
history of diabetes, hypertension, smoking status, alcohol,
and adjuvant treatments) were obtained at the time of patient
recruitment.
Patients were administered whole breast RT with conven-
tional fractions (50-50.4 Gy, 1.8-2 Gy/fraction) followed by a
12-18 Gy electron boost. In most cases, irradiation was per-
formed with photon beams from a 4 MeV linear accelerator
using 3-dimensional conformal RT (3D-CRT) and in 7.5%
with 2-dimensional radiation therapy (2D-RT) for planning.
All treatments were equivalent in terms of biologically effec-
tive dose.
The acute side effects of RT developing in the skin within
the radiation field of the breast were used for measurement
of clinical radiosensitivity. The severity of these reactions
was assessed using the scoring system of the Radiation Ther-
apy Oncology Group (RTOG) criteria. Development of acute
side effects grade ≥ 2 was considered to indicate increased
sensitivity for acute effects. Patients with minimal or no skin
reactions (grade < 2) were included in the control group.
Grade 2 was defined by at least one marked erythema or
moist desquamation, grade 3 as confluent moist desquama-
tion or severe edema, and grade 4 was defined by ulceration,
hemorrhage, or necrosis. The occurrence and severity of
acute skin reactions were determined during and after RT,
given the highest degree of toxicity.
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The research protocol was approved by the Ethics Com-
mittee of the Human Genetics Association and was con-
ducted in agreement with the Helsinki Declaration. Informed
consent was obtained from patients before inclusion in the
study and sample collection. 
2. DNA extraction and genotyping of polymorphisms
The SNPs selected and their dbSNP ID (rs) were as follows:
GSTP1 Ile105Val (rs1695), SOD2 V16A (rs4880), NOS3 G894T
(rs1799983), and GSTA1 C69T (rs3957356). Total genomic
DNA was extracted from blood leukocytes and swabbing
oral mucosa. DNA quality was evaluated by spectropho-
tometer analysis (Nanovue, GE Heathcare, Buckinghams-
hire, UK). Samples were centrifuged at 12,000 rpm for 4 min-
utes. The supernatant was discarded, followed by successive
washes with TE buffer (10 mM Tris-HCl, 0.1 mM EDTA) for
removal of all traces of erythrocytes. The cell pellet obtained
from the samples was incubated for 24 hours at 56°C in 300
μL of extraction buffer (50 mM Tris-HCl pH 8.5, 1 mM EDTA,
1% Triton X-100, and 0.5% Tween 20) and 10 μL of proteinase
K (10 mg/mL, Promega, Madison, WI). Proteinase K was
|inactivated by boiling for 10 minutes. DNA samples were
stored at –20°C until use; 3 μL DNA were then used in per-
formance of polymerase chain reaction (PCR) amplifications.
Polymorphisms were determined using the PCR-based 
restriction-fragment-length-polymorphism technique. PCR
was performed in a total reaction volume of 25 μL using Taq
DNA polymerase (Genbiotech, Buenos Aires, Argentina).
Primer pairs were used at a concentration of 0.5 pmol/μL
(Table 1). For all polymorphisms, cycling conditions were
94°C for 3 minutes, followed by 35 cycles of 94°C for 30 sec-
onds, 55-57°C for 30 seconds, and 72°C for 30 seconds, with
a final extension of 72°C for 3 minutes. PCR-products har-
boring the SNPs were digested overnight with 5 U of restric-
tion enzymes (total volume, 15 mL; New England Biolabs, 
Ipswich, MA; Thermo Fisher Scientific, Fremont, CA) at the
recommended temperatures. Digestions were as follows:
GSTP1 with Alw26I to yield fragments of 83 bp and 93 bp;
NOS3 with MboI (87 bp and 119 bp), SOD2 with BsaWI (74
bp and 85 bp), and GSTA1 with MnII (77 bp and 70 bp). They
were resolved on 8%-10% polyacrylamide gels and visual-
ized after staining with ethidium bromide.
3. Statistical analyses 
Each polymorphism was tested for deviation from Hardy-
Weinberg equilibrium (HWE) by comparing the observed
and expected genotype frequencies using Pearson’s chi-
square test. The effect of clinical factors and genetic variables
on the risk of RT-induced acute skin toxicity was evaluated
by univariate logistic regression analysis. Odds ratios (ORs)
and their 95% confidence intervals (CI) were used as esti-
mates of relative risk. Variables were analyzed by calculating
correlations. Principal component analysis was used to 
determine the degree of association between variables and
which variables contributed to variations in radiotoxicity.
Statistical analyses were performed using the IBM SPSS ver.
19 (IBM Co., Armonk, NY).
Results
1. SNPs and radiotoxicity
Sixty-five patients (81.2%) presented adverse side effects,
32 (40%) experienced moderate to severe acute skin toxicity
(RTOG grade 2-4), while 33 (41.2%) manifested minimal
acute skin reactions (RTOG grade 1). Pulmonary toxicity was
not recorded in any of the patients.
Table 1. Features of polymorphism genotyping
Gene SNP dbSNP ID Primer F (5´-3´) Primer R (5´-3´)
Annealing PCR product Restriction
temperature (°C) size (bp) enzymes
GSTP1 A313G rs1695 ACCCCAGGGCTC TGAGGGCACAAG 56 176 Alw26I
TATGGGAA AAGCCCCT
SOD2 T47C rs4880 CTGCGTAGACGG TGATGTGAGGTT 57 159 BsaWI
TCCCG CCAGGGC
NOS3 G894T rs1799983 CATGAGGCTCA AGTCAATCCCTT 55 206 MboI
GCCCCAGAAC TGGTGCTCAC
GSTA1 C69T rs3957356 GCATCAGCTTGC AAACGCTGTCAC 55 401 MnII
CCTTCA CGTCCTG
SNP, single nucleotide polymorphism; PCR, polymerase chain reaction.
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All genotype distributions were in HWE both in control
and in individuals with radiodermitis grade ≥ 2 (p > 0.05).
The observed minor allele frequencies of GSTP1, NOS3,
SOD2, and GSTA1 were compared with those reported for
the American population from phase 1 of the 1000 Genomes
Project in the dbSNP database (Fig. 1). 
The results of univariate analysis showed no significant 
association of the polymorphisms in oxidative stress genes
with risk for development of acute skin reactions (cut-off 
p-value < 0.05) (Table 2) in the patients studied. On the other
hand, in analysis of only patients treated with neo-adjuvant
chemotherapy (n=25, 31.25%), homozygous carriers of the
NOS3 894T allele (OR, 9.8; 95% CI, 211.6 to 0.45; p=0.041)
were at higher risk of developing acute skin reactions. How-
ever, no statistically significant OR was observed with other
SNPs in this group.
2. Other factors affecting radiotoxicity
The clinical characteristics of patients are listed in Table 3.
Mean age was 59.44 years. Older women presented higher
radio-toxicity. Differences were observed in 33 patients grade
≥ 2 (mean age, 66.30 years) and 47 patients grade < 2 (mean
age, 58.87 years). 
None of the patients reported previous therapeutic expo-
sure to ionizing or non-ionizing radiation, except for one
who had undergone radiotherapy twice in the same breast
with a 38-month interval between treatments who presented
significant radiotoxicity (grade 4).
The reported vitamin and dietary supplements consumed
by patients, individual factors including smoking habits, 
alcohol consumption, anemia, hypertension, diabetes, and
severe acute radiotoxicity were not significant (data not
shown). However, we found a positive correlation of BMI
(OR, 3.14; 95% CI, 8.5338 to 1.1274; p=0.0222) and breast size
(OR, 5.11; 95% CI, 17.04 to 1.54; p=0.004) with acute skin 
reactions. Thus, patients with BMI > 25 kg/m2 and medium
and large breast were at greater risk of developing radioder-
mitis. 
In addition, when comparing type of treatment (2D-RT
and 3D-CRT) and radiotoxicity, no significant differences
were observed (OR, 1.44; 95% CI, 8.37 to 0.25; p=0.68).
Discussion
This is the first study conducted in our country for analysis
of gene variants related to DNA damage response pathways
after ionization radiation on the risk of developing acute skin
radiation toxicity in patients with BC receiving RT after BCS.
These reactions can affect the therapeutic program and
worsen the patient quality of life [4,12]. 
Individual radiosensitivity is a phenotype that can occur
in several phases of treatment. Because its intensity depends
on RT-related factors and individuals, we characterized dif-
ferent parameters in our population and correlated them
with radio-induced skin reactions. 
According to Schnur et al. [13], the majority of BC patients
(74%-100%) will experience radiodermitis during the course
of RT. Our results agree with the above mentioned results
since 81.2% of our patients had skin toxicity, with a higher
incidence of grades 1 and 2 (68.8%) compared with grades 3
and 4 (12.5%) (Table 3).
As indicated by radiation oncologists, grades 1 and 2 are
usually tolerated by the patient, who can continue with RT.
However, the toxicity of grades 3 and 4 requires the suspen-
sion of treatment and intervention with therapeutic agents.
In this study, all patients concluded with the total dose
planned.
The pathogenesis of normal tissue is a dynamic process ini-
tiated in response to cell death. In recent years, the role of
free radicals in the maintenance of chronic stress which 
interferes with the recovery of normal tissue has been eval-
uated. The emerging concept holds that there is no recovery
of chronic tissue damage caused by ROS, pro-inflammatory
cytokines and chemokines, which result in progressive dam-
age and end in tissue injury [14]. Considering the pathways
previously mentioned and that radiosensitivity is a polygenic
trait, in this study the genes analyzed were selected based on
their role in the establishment of antioxidant status. Thereby,
we began evaluating SNPs GSTP1 Ile105Val (rs1695) and
GSTA1 C69T (rs3957356). The low activity variant of GSTP1
was associated with a greater than 2-fold risk for acute reac-
tions of the irradiated skin in BC patients [15]. In addition,
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Fig. 1.  Distribution of each allele for studied genes. Obs,
observed; Exp, expected; AMR, American.
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Falvo et al. [16] reported a protective role as a trend for wt
GSTP1. However, and the same as in another report [17], in
this study no statistically significant association was obser-
ved between GSTP1 and radiosensitivity. On the other hand,
an association between GSTA1 (rs3957356) and adverse skin
effects could not be demonstrated. Opposite to this, Falvo et
al. [16] reported an association between wt GSTA1 and ery-
thema, and Ambrosone et al. [15] found this allele as a pro-
tective agent. 
Regarding SOD2 gene, none of the genotypes was associ-
ated with risk of radiotoxicity, in coincidence with Ahn et al.
[12]. However, Ambrosone et al. [18] found that genotypes
related to higher oxidative stress were associated with better
BC survival. 
Finally, we found association between acute radiotoxicity
and NOS3 homozygous T allele in patients who received
neoadjuvant chemotherapy. The enzyme NOS3 catalyzes the
production of the free radical nitric oxide (NO), and the
894G>T variant in the NOS3 gene results in a 298Glu>Asp
substitution that alters susceptibility to cleavage and leads
to reduced NO levels [19]. Probably, the decreased NO
would produce a lower vasodilator mediated effect and, 
consequently, a lower intake of oxygen and nutrients needed
for tissue reconstruction. Likewise, it could exacerbate
chemotherapy-induced damage in situ, considering that 
anthracycline-mediated oxidative stress is responsible for
membrane lipid peroxidation. This free radical activates the
immune system, which is central to the establishment of RT
side effects [14]. Because this trait is influenced by quantita-
tive genetics, a multivariate analysis was performed, without
achieving positive correlations. This is in line with most stud-
ies in BC patients [20] showing no significant association 
between the vast majority of SNPs and acute effects.
In addition to genetic analysis, others factors influencing
the development of radiosensitivity were considered, includ-
ing the clinical data recorded and the characteristics associ-
ated with treatment. In the case of the age of patients, older
Table 2. Association between GSTP1, SOD2, NOS3, and GSTA1 polymorphisms and risk of developing acute skin toxicity
after RT in BC patients
Gene Genotype No. (%) Grade 0-1 ≥ Grade 2 OR (95% CI) p-value
GSTP1 AA 25 (31.25) 15 10
AG 38 (47.50) 24 14 1.0781 (2.8241-0.4116) 0.8783
GG 17 (21.25) 8 9 1.8281 (5.3813-0.6210) 0.2698
SOD2 TT 18 (22.50) 9 9
TC 45 (56.25) 27 18 0.6316 (1.8154-0.2197) 0.3916
CC 17 (21.25) 11 6 0.7273 (2.2131-0.2389) 0.574
NOS3 GG 30 (37.50) 16 14
GT 34 (42.50) 22 12 0.7004 (1.7521-0.28) 0.4459
TT 16 (20) 9 7 1.1367 (3.4375-0.3759) 0.8203
GSTA1 CC 16 (20) 11 5
CT 50 (62.50) 29 21 1.7111 (5.4957-0.5328) 0.3636
TT 14 (17.50) 7 7 1.5385 (4.8986-0.4831) 0.464
RT, radiation therapy; BC, breast cancer; OR, odds ratio; CI, confidence interval.
Table 3. Clinical and demographic characteristics of BC
patients 
Characteristic No. (%) (n=80)
Age 
Mean (range, yr) 59 (26-79)
BMI (kg/m2)
< 25 32 (42.7)
> 25 43 (57.3)
Tumor localization
Left breast 49 (61.3)
Right breast 31 (38.7)
Chemotherapy neoadjuvant (yes/no) 25/50
Diabetes (yes/no) 10/69
Hypertension (yes/no) 30/49
Smoking (yes/no) 19/57
Alcohol consumption (yes/no) 4/72
Skin reactions (RTOG)
Grade 0 15 (18.8)
Grade I 33 (41.3)
Grade II 22 (27.5)
Grade III 8 (10)
Grade IV 2 (2.5)
BC, breast cancer; BMI, body mass index; RTOG, Radia-
tion Therapy Oncology Group.
women presented higher toxicity. These results argue against
other studies suggesting that RT is well tolerated in old 
patients [21]. Concerning smoking, no significant association
was found, probably due to the low incidence of smokers in
this population. In the case of hypertension, at least 38% of
patients were hypertensive, and no statistical significance
was observed with relation to the severity of skin reactions.
Only 8% of patients presented with diabetes. However, no
other study has shown diabetes as a predisposing factor for
adverse skin reactions [21,22]. In agreement with these 
results, Terrazzino et al. [9] reported that no solid that dia-
betes mellitus, hypertension or smoking status were predis-
posing factors for acute radiosensitivity [22,23]. 
Among other clinical features investigated, the results of
multivariate analysis showed that breast size and BMI were
predictors of acute skin toxicity, in agreement with Terrazz-
ino et al. [9]. Several studies consider that breast size is 
important because the volume irradiated is a factor related
to radiation and interferes in the incidence and severity of
side effects. Larger breast volumes require application of
larger doses on the skin to reach the desired dosage in tissue
and deeper structures [9,21]. Our results substantiate those
showing a more intense skin reaction in medium and large
breasts [24]. In addition, Twardella et al. [25] previously 
reported an association of overweight/obesity (BMI > 25
kg/m2) with an increased risk of acute radiotoxicity. In rela-
tion to this parameter, whereas individuals with normal BMI
presented one third of acute effects grade ≥ 2, overweight/
obesity patients showed half of these effects.
Conclusion
Given the importance of BC as a frequent pathology in our
region, studies are important not only to improve prevention
but also to optimize treatment. In relation to RT, it is impor-
tant to elucidate the mechanisms underlying radiotoxicity as
well as to establish or confirm associations between genetic
variants and risk of developing severe acute effects. Our 
results could not prove the association between radiotoxicity
and oxidative stress genes, due in part to the small sample
size and the low penetrance alleles. However, considering
that radiotoxicity is a multifactorial trait, the participation of
other mutations in these genes or in sequences regulated by
them, epigenetic changes or other candidate genes cannot be
excluded.
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